EUCTR2007-000338-38-DE进行中（未招募）不适用
A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREAMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- •1.written informed consent
- •2.histologically or cytologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas not amenable to curative radiotherapy or surgery.
- •3.measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (ie, target lesions that can be accurately measured in at least one dimension with the longest diameter = 20 mm using conventional techniques or = 10 mm using spiral computed tomography [CT] scan).
- •4.able to take medications orally.
- •5.at least18 years of age or older.
- •6.Karnofsky Performance Status (KPS) = 70% (see Appendix A).
- •7.life expectancy of = 12 weeks.
- •8.adequate organ function as defined by the following criteria:
- •oTransaminases AST (SGOT) and ALT (SGPT) = 2.5 times the upper limit of normal (ULN).
- •o If liver function abnormalities are due to underlying liver metastasis, then AST (SGOT) and ALT (SGPT) may be = 5 times ULN.
- •oTotal serum bilirubin = 3.0 times ULN (if due to underlying liver metastasis, then total bilirubin may be = 5 times ULN).
- •oAbsolute granulocyte count = 1,500/mm3 (ie, = 1.5 x 10^9/L by International Units [IU]).
- •oPlatelet count = 100,000/mm3 (IU: = 100 x 10^9/L).
- •oHemoglobin value = 9.0 g/dL.
- •oCalculated creatinine clearance = 60 mL/min (based on serum creatinine) (Cockcroft-Gault formula).
- •9.willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •10.both female and male patients must use adequate methods of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:
- •1.had treatment with any of the following within the specified time frame prior to study drug administration:
- •a.Any prior anticancer chemotherapy.
- •b.Radiation therapy to a target lesion unless there was evidence of PD after radiotherapy (and this target lesion must not be the only site of measurable disease).
- •c.Any radiotherapy within the previous 3 weeks.
- •d.Any investigational agent received either concurrently or within the last 30 days.
- •e.Current enrollment in another clinical trial.
- •2. Major surgery within the previous 3 weeks.
- •3. Symptomatic brain metastasis not controlled by corticosteroids.
- •4. Leptomeningeal metastasis.
- •5. Previous or concurrent malignancy other than pancreatic cancer except adequately treated carcinoma in-situ of the cervix or non-melanoma skin cancer.
- •6. Uncontrolled ascites requiring drainage at least twice a week.
- •7. Other serious illness or medical condition(s) including, but not limited to, the following:
- •o-Uncontrolled congestive heart failure (New York Heart Association [NYHA] Class III or IV, see Appendix F), angina pectoris, arrhythmias, or hypertension.
- •o-Active infection.
- •o-Known (at time of entry) gastrointestinal disorder, including malabsorption, chronic nausea, vomiting, or diarrhea, present to the extent that it might interfere with oral intake and absorption of study medication.
- •o-Poorly controlled diabetes mellitus.
- •-Psychiatric disorder that may interfere with consent and/or protocol compliance.
- •-Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
- •-Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study.
- •8. pregnant or lactating female.
- •9. known hypersensitivity to Anti-EGFR antibodies.
- •10. with reproductive potential who refuses to use an adequate means of contraception (including male patients).
- •11. has been treated with gemcitabine in an adjuvant situation
研究者
相似试验
进行中（未招募）
1 期
A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Canceron-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002328-18-GRF. Hoffman-La Roche Ltd.375
进行中（未招募）
1 期
A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared with Atezolizumab Intravenous in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2018-002328-18-LVF. Hoffman-La Roche Ltd.387
进行中（未招募）
1 期
A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared with Atezolizumab Intravenous in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Canceron-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002328-18-BGF. Hoffman-La Roche Ltd.387
进行中（未招募）
1 期
A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared with Atezolizumab Intravenous in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2018-002328-18-HUF. Hoffman-La Roche Ltd.387
进行中（未招募）
不适用
A PHASE II MULTI-CENTER, RANDOMIZED, BLINDED STUDY OF 14 WEEKS DURATION COMPARING THE EFFECT OF CRx-139 PLUS DMARD THERAPY TO THAT OF STEROID PLUS DMARD THERAPY USING ACR-20 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS PARTIALLY RESPONSIVE TO THE DMARD. - CRx-139-RAACTIVE RHEUMATOID ARTHRITISEUCTR2004-004995-35-ATCombinatoRx, Inc.220